MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome - UTU Tutkimustietojärjestelmä

A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome

Tekijät: Maria NI, Brkic Z, Waris M, van Helden-Meeuwsen CG, Heezen K, van de Merwe JP, van Daele PL, Dalm VASH, Drexhage HA, Versnel MA

Kustantaja: BMJ PUBLISHING GROUP

Julkaisuvuosi: 2014

Journal: Annals of the Rheumatic Diseases

Tietokannassa oleva lehden nimi: ANNALS OF THE RHEUMATIC DISEASES

Lehden akronyymi: ANN RHEUM DIS

Vuosikerta: 73

Numero: 6

Aloitussivu: 1052

Lopetussivu: 1059

Sivujen määrä: 8

ISSN: 0003-4967

DOI: https://doi.org/10.1136/annrheumdis-2012-202552

Tiivistelmä

Conclusions The MxA assays were excellent tools to assess IFN type I activity in pSS, MxA-EIA being the most practical. MxA levels associate with features of active disease and are reduced in hydroxychloroquine-treated patients, suggesting the clinical applicability of MxA in stratifying patients according to IFN positivity.